Upgrade to SI Premium - Free Trial

Baird Upgrades Quest Diagnostics (DGX) to Outperform

October 23, 2024 3:24 AM
Baird analyst Eric Coldwell upgraded Quest Diagnostics (NYSE: DGX) from Neutral to Outperform with a price target of $182.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Upgrades

Next Articles